Since 2004, the DNDi office in Malaysia has supported a variety of R&D activities across the Asian region, including key preclinical and early clinical studies for the FACT Project, as well as the fostering of the PAN4ND, a regional research platform that focused on the discovery and development of natural substances as therapeutics to neglected diseases. The office is now involved in DNDi’s hepatitis C clinical studies that will take place in the country.





DNDi in South-East Asia

L10-7, Menara Sentral Vista,
150, Jln Sultan Abdul Samad
Brickfields
50470 Kuala Lumpur
Malaysia

Tel: +60 3 2716 4159



  • After completion of patient recruitment in the sofosbuvir/ravidasvir clinical study for hepatitis C in Malaysia, start of recruitment in Thailand
  • Approval by Malaysia of a “government use” licence to secure access to more affordable treatments for hepatitis C
  • Agreement signed between pharmaceutical companies Pharmaniaga (Malaysia) and Pharco Pharmaceuticals (Egypt), and DNDi to supply affordable hepatitis C treatment in Malaysia
  • DNDi collaborates closely with the Malaysian MoH to develop and produce a new affordable HCV combination treatment.
  • Clinical trial starts in six sites in Malaysia to test the sofosbuvir and ravidasvir combination in 220 HCV patients.
  • DNDi engages R&D and civil society actors in Malaysia, Thailand, and other South-East Asian countries.
  • DNDi office moves to Kuala Lumpur and new Head of Office is hired.